Fusion protein of retinol-binding protein and albumin domain III reduces liver fibrosis

Hong Sik Lee, Hyeyeun Jeong, Sangeun Park, Wonbaek Yoo, Soyoung Choi, Kyungmin Choi, Min-Goo Lee, Mihwa Lee, Dae-Ryong Cha, Young Sik Kim, Jeeyoung Han, Wonkon Kim, Sun-Hwa Park, Jun Seo Oh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Activated hepatic stellate cells (HSCs) play a key role in liver fibrosis, and inactivating HSCs has been considered a promising therapeutic approach. We previously showed that albumin and its derivative designed for stellate cell-targeting, retinol-binding protein-albumin domain III fusion protein (referred to as R-III), inactivate cultured HSCs. Here, we investigated the mechanism of action of albumin/R-III in HSCs and examined the anti-fibrotic potential of R-III in vivo. R-III treatment and albumin expression downregulated retinoic acid (RA) signaling which was involved in HSC activation. RA receptor agonist and retinaldehyde dehydrogenase overexpression abolished the anti-fibrotic effect of R-III and albumin, respectively. R-III uptake into cultured HSCs was significantly decreased by siRNA-STRA6, and injected R-III was localized predominantly in HSCs in liver. Importantly, R-III administration reduced CCl<inf>4</inf>- and bile duct ligation-induced liver fibrosis. R-III also exhibited a preventive effect against CCl<inf>4</inf>-inducd liver fibrosis. These findings suggest that the anti-fibrotic effect of albumin/R-III is, at least in part, mediated by downregulation of RA signaling and that R-III is a good candidate as a novel anti-fibrotic drug.

Original languageEnglish
Pages (from-to)819-830
Number of pages12
JournalEMBO Molecular Medicine
Volume7
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Retinol-Binding Proteins
Hepatic Stellate Cells
Liver Cirrhosis
Albumins
Proteins
Tretinoin
Cultured Cells
Down-Regulation
Retinaldehyde
Retinoic Acid Receptors
Protein Domains
Bile Ducts
Small Interfering RNA
Ligation
Oxidoreductases
Liver
Pharmaceutical Preparations

Keywords

  • Albumin
  • Anti-fibrotic drug
  • Fibrosis
  • Hepatic stellate cell
  • Retinoic acid

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Fusion protein of retinol-binding protein and albumin domain III reduces liver fibrosis. / Lee, Hong Sik; Jeong, Hyeyeun; Park, Sangeun; Yoo, Wonbaek; Choi, Soyoung; Choi, Kyungmin; Lee, Min-Goo; Lee, Mihwa; Cha, Dae-Ryong; Kim, Young Sik; Han, Jeeyoung; Kim, Wonkon; Park, Sun-Hwa; Oh, Jun Seo.

In: EMBO Molecular Medicine, Vol. 7, No. 6, 01.06.2015, p. 819-830.

Research output: Contribution to journalArticle

Lee, Hong Sik ; Jeong, Hyeyeun ; Park, Sangeun ; Yoo, Wonbaek ; Choi, Soyoung ; Choi, Kyungmin ; Lee, Min-Goo ; Lee, Mihwa ; Cha, Dae-Ryong ; Kim, Young Sik ; Han, Jeeyoung ; Kim, Wonkon ; Park, Sun-Hwa ; Oh, Jun Seo. / Fusion protein of retinol-binding protein and albumin domain III reduces liver fibrosis. In: EMBO Molecular Medicine. 2015 ; Vol. 7, No. 6. pp. 819-830.
@article{81f4f95a37fa4f9e833c86d6affc705d,
title = "Fusion protein of retinol-binding protein and albumin domain III reduces liver fibrosis",
abstract = "Activated hepatic stellate cells (HSCs) play a key role in liver fibrosis, and inactivating HSCs has been considered a promising therapeutic approach. We previously showed that albumin and its derivative designed for stellate cell-targeting, retinol-binding protein-albumin domain III fusion protein (referred to as R-III), inactivate cultured HSCs. Here, we investigated the mechanism of action of albumin/R-III in HSCs and examined the anti-fibrotic potential of R-III in vivo. R-III treatment and albumin expression downregulated retinoic acid (RA) signaling which was involved in HSC activation. RA receptor agonist and retinaldehyde dehydrogenase overexpression abolished the anti-fibrotic effect of R-III and albumin, respectively. R-III uptake into cultured HSCs was significantly decreased by siRNA-STRA6, and injected R-III was localized predominantly in HSCs in liver. Importantly, R-III administration reduced CCl4- and bile duct ligation-induced liver fibrosis. R-III also exhibited a preventive effect against CCl4-inducd liver fibrosis. These findings suggest that the anti-fibrotic effect of albumin/R-III is, at least in part, mediated by downregulation of RA signaling and that R-III is a good candidate as a novel anti-fibrotic drug.",
keywords = "Albumin, Anti-fibrotic drug, Fibrosis, Hepatic stellate cell, Retinoic acid",
author = "Lee, {Hong Sik} and Hyeyeun Jeong and Sangeun Park and Wonbaek Yoo and Soyoung Choi and Kyungmin Choi and Min-Goo Lee and Mihwa Lee and Dae-Ryong Cha and Kim, {Young Sik} and Jeeyoung Han and Wonkon Kim and Sun-Hwa Park and Oh, {Jun Seo}",
year = "2015",
month = "6",
day = "1",
doi = "10.15252/emmm.201404527",
language = "English",
volume = "7",
pages = "819--830",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Fusion protein of retinol-binding protein and albumin domain III reduces liver fibrosis

AU - Lee, Hong Sik

AU - Jeong, Hyeyeun

AU - Park, Sangeun

AU - Yoo, Wonbaek

AU - Choi, Soyoung

AU - Choi, Kyungmin

AU - Lee, Min-Goo

AU - Lee, Mihwa

AU - Cha, Dae-Ryong

AU - Kim, Young Sik

AU - Han, Jeeyoung

AU - Kim, Wonkon

AU - Park, Sun-Hwa

AU - Oh, Jun Seo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Activated hepatic stellate cells (HSCs) play a key role in liver fibrosis, and inactivating HSCs has been considered a promising therapeutic approach. We previously showed that albumin and its derivative designed for stellate cell-targeting, retinol-binding protein-albumin domain III fusion protein (referred to as R-III), inactivate cultured HSCs. Here, we investigated the mechanism of action of albumin/R-III in HSCs and examined the anti-fibrotic potential of R-III in vivo. R-III treatment and albumin expression downregulated retinoic acid (RA) signaling which was involved in HSC activation. RA receptor agonist and retinaldehyde dehydrogenase overexpression abolished the anti-fibrotic effect of R-III and albumin, respectively. R-III uptake into cultured HSCs was significantly decreased by siRNA-STRA6, and injected R-III was localized predominantly in HSCs in liver. Importantly, R-III administration reduced CCl4- and bile duct ligation-induced liver fibrosis. R-III also exhibited a preventive effect against CCl4-inducd liver fibrosis. These findings suggest that the anti-fibrotic effect of albumin/R-III is, at least in part, mediated by downregulation of RA signaling and that R-III is a good candidate as a novel anti-fibrotic drug.

AB - Activated hepatic stellate cells (HSCs) play a key role in liver fibrosis, and inactivating HSCs has been considered a promising therapeutic approach. We previously showed that albumin and its derivative designed for stellate cell-targeting, retinol-binding protein-albumin domain III fusion protein (referred to as R-III), inactivate cultured HSCs. Here, we investigated the mechanism of action of albumin/R-III in HSCs and examined the anti-fibrotic potential of R-III in vivo. R-III treatment and albumin expression downregulated retinoic acid (RA) signaling which was involved in HSC activation. RA receptor agonist and retinaldehyde dehydrogenase overexpression abolished the anti-fibrotic effect of R-III and albumin, respectively. R-III uptake into cultured HSCs was significantly decreased by siRNA-STRA6, and injected R-III was localized predominantly in HSCs in liver. Importantly, R-III administration reduced CCl4- and bile duct ligation-induced liver fibrosis. R-III also exhibited a preventive effect against CCl4-inducd liver fibrosis. These findings suggest that the anti-fibrotic effect of albumin/R-III is, at least in part, mediated by downregulation of RA signaling and that R-III is a good candidate as a novel anti-fibrotic drug.

KW - Albumin

KW - Anti-fibrotic drug

KW - Fibrosis

KW - Hepatic stellate cell

KW - Retinoic acid

UR - http://www.scopus.com/inward/record.url?scp=84930180632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930180632&partnerID=8YFLogxK

U2 - 10.15252/emmm.201404527

DO - 10.15252/emmm.201404527

M3 - Article

C2 - 25864124

AN - SCOPUS:84930180632

VL - 7

SP - 819

EP - 830

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 6

ER -